An Open-Label Study of Brentuximab Vedotin + Adriamycin, Vinblastine, and Dacarbazine in Pediatric Patients With Advanced Stage Newly Diagnosed Hodgkin Lymphoma
Phase of Trial: Phase I/II
Latest Information Update: 22 Nov 2017
At a glance
- Drugs Brentuximab vedotin (Primary) ; Dacarbazine; Doxorubicin; Vinblastine
- Indications Hodgkin's disease
- Focus Adverse reactions; Therapeutic Use
- Sponsors Takeda Oncology
- 15 Sep 2017 Planned End Date changed from 28 Feb 2020 to 29 Oct 2021.
- 15 Sep 2017 Planned primary completion date changed from 28 Feb 2020 to 30 Jun 2020.
- 31 Jul 2017 Status changed from not yet recruiting to recruiting.